StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (0.00%)

Close on Nov 17, 2026Market cap $6.42MP/E –Yield –

Theriva Biologics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Theriva Biologics's ebitda for the twelve months ending Jun 30, 2026 was -$11.82M. For fiscal 2025 it was -$23.94M. The highest annual figure on record is -$9.96M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.94M–
FY2024Dec 31, 2024-$26.21M–
FY2023Dec 31, 2023-$21.30M–
FY2022Dec 31, 2022-$21.50M–
FY2021Dec 31, 2021-$14.19M–
FY2020Dec 31, 2020-$9.96M–
FY2019Dec 31, 2019-$15.42M–
FY2018Dec 31, 2018-$17.30M–
FY2017Dec 31, 2017-$26.01M–
FY2016Dec 31, 2016-$39.10M–
FY2015Dec 31, 2015-$40.91M–
FY2014Dec 31, 2014-$20.48M–
FY2013Dec 31, 2013-$12.30M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.27M–
Q1 FY2026Mar 31, 2026-$2.10M–
Q4 FY2025Dec 31, 2025-$2.04M–
Q3 FY2025Sep 30, 2025-$4.41M–
Q2 FY2025Jun 30, 2025-$13.11M–
Q1 FY2025Mar 31, 2025-$4.39M–
Q4 FY2024Dec 31, 2024-$4.55M–
Q3 FY2024Sep 30, 2024-$7.85M–
Q2 FY2024Jun 30, 2024-$8.45M–
Q1 FY2024Mar 31, 2024-$5.35M–
Q4 FY2023Dec 31, 2023-$6.18M–
Q3 FY2023Sep 30, 2023-$4.19M–
Q2 FY2023Jun 30, 2023-$5.79M–
Q1 FY2023Mar 31, 2023-$5.15M–
Q4 FY2022Dec 31, 2022-$7.29M–
Q3 FY2022Sep 30, 2022-$4.96M–
Q2 FY2022Jun 30, 2022-$5.01M–
Q1 FY2022Mar 31, 2022-$4.23M–
Q4 FY2021Dec 31, 2021-$5.25M–
Q3 FY2021Sep 30, 2021-$3.26M–
Q2 FY2021Jun 30, 2021-$3.17M–
Q1 FY2021Mar 31, 2021-$2.50M–
Q4 FY2020Dec 31, 2020-$2.10M–
Q3 FY2020Sep 30, 2020-$2.06M–
Q2 FY2020Jun 30, 2020-$2.83M–
Q1 FY2020Mar 31, 2020-$2.97M–
Q4 FY2019Dec 31, 2019-$3.15M–
Q3 FY2019Sep 30, 2019-$5.18M–
Q2 FY2019Jun 30, 2019-$3.58M–
Q1 FY2019Mar 31, 2019-$3.51M–
Q4 FY2018Dec 31, 2018-$3.19M–
Q3 FY2018Sep 30, 2018-$4.25M–
Q2 FY2018Jun 30, 2018-$4.93M–
Q1 FY2018Mar 31, 2018-$4.92M–
Q4 FY2017Dec 31, 2017-$5.71M–
Q3 FY2017Sep 30, 2017-$5.79M–
Q2 FY2017Jun 30, 2017-$6.42M–
Q1 FY2017Mar 31, 2017-$8.09M–
Q4 FY2016Dec 31, 2016-$10.16M–
Q3 FY2016Sep 30, 2016-$9.10M–

More Theriva Biologics figures

See a number that looks wrong?